Abstract
purpose. To determine the frequency of optic nerve invasion in uveal melanoma, to identify clinical factors associated with optic nerve invasion, and to analyze the metastatic pattern and the association with survival.
methods. All iris, ciliary body, and choroidal melanomas (N = 2758) examined between 1942 and 2001 at the Eye Pathology Institute, University of Copenhagen, Denmark, and the Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark, were reviewed. Cases with optic nerve invasion were identified and subdivided into prelaminar or laminar invasion and postlaminar invasion. Clinical characteristics were compared with those from 85 cases randomly drawn from all ciliary body and choroidal melanomas without optic nerve invasion from the same period. Survival data were obtained by the Kaplan-Meier method, and the Mantel-Cox log-rank test was used to test differences in survival among the three patient groups.
results. Optic nerve invasion was found in 157 uveal melanomas (5.7%; 95% confidence interval [CI], 4.8%–6.6%). Frequency varied during the observation period between 5% and 7%. Only choroidal and ciliary body melanomas were found to invade the optic nerve. Eighty-five (54%) were confined to the prelaminar or laminar part, and 72 (46%) were confined to the postlaminar part. Increased intraocular pressure (IOP) and juxtapapillary location were associated with prelaminar or laminar invasion and postlaminar invasion. Age older than 70 years, reduced vision to light perception or worse, nonvisible fundus, and large (>15 mm) tumor size were associated with postlaminar spread. In univariate analysis, patients with postlaminar invasion had significantly higher all-cause and melanoma-related mortality than the other patients.
conclusions. Optic nerve invasion in uveal melanoma is found in 1 in 20 patients. Visible juxtapapillary melanoma or loss of light perception should make the clinician suspicious of melanoma with optic nerve invasion, and special awareness of postlaminar spread should be addressed when increased IOP is present independently of decreased visual acuity and tumor location.
Uveal melanoma is the most frequent primary intraocular malignant tumor in adults; in Scandinavia, the incidence rate is 5.3 to 8.7 per million person-years.
1 2 3 4 The tumor has a great propensity to metastasize and to affect the liver in particular.
3 5 6 Local spread occurs through the overlying Bruch membrane, giving access to the subretinal space, or toward the orbit (through the sclera, most often along ciliary vessels and nerves). Uveal melanoma infiltrates the optic nerve in only 0.6% to 5% of patients and has been associated with high intraocular pressure, non–spindle cell type, juxtapapillary location, and blindness.
3 7 8 9 10 11 12 13 14 15
The uveal melanoma material examined between 1942 and 2001 at the Eye Pathology Institute, University of Copenhagen, and the Institute of Pathology, Aarhus University Hospital, was reviewed to determine the frequency of optic nerve invasion and to identify clinical factors associated with optic nerve invasion. Furthermore, the metastatic pattern was investigated, and survival analyses were performed to determine the association between survival and optic nerve invasion.
At the Eye Pathology Institute, University of Copenhagen, and the Institute of Pathology, Aarhus University Hospital, 2758 eyes enucleated for uveal melanoma between 1942 and 2001 were examined. These eyes constituted all enucleated eyes with uveal melanoma during this period in Denmark. All pathology reports and histology specimens were reviewed, and 157 uveal melanomas with optic nerve invasion were identified. A control group of 85 patients was randomly chosen from the same period from the group of patients with choroidal or ciliary body melanoma without optic nerve invasion because no iris melanomas invaded the optic nerve. In total, 242 patients with uveal melanoma were enrolled in this study.
Reports from admitting hospitals were collected, and the following data on each patient were registered: sex, date of birth, date of histopathologic diagnosis, visual acuity, intraocular pressure (IOP), funduscopic examination, signs of extraocular growth at surgery, ocular surgery, radiotherapy, and orbital recurrence. Visual acuity and intraocular pressure were only included if these recordings were obtained within 2 weeks before enucleation. The tumor was classified as juxtapapillary if the clinician observed during funduscopic examination that the tumor was touching the optic disc. Signs of extraocular growth were graded as positive if the admitting physician had noted this in the surgical report or in the admission note. All pathology reports at the Eye Pathology Institute from 1942 to 2005 were also reviewed to detect orbital recurrences. Furthermore, the Danish Cancer Registry (DCR) was studied to detect orbital recurrences not treated with surgery.
Registrations at the DCR and the Registry of Cause of Death were studied, and data on date of death, cause of death, and metastases were collected. Furthermore, autopsy reports were collected. Metastases were registered if they had been confirmed by computed tomography (CT), ultrasonography, surgery, or autopsy. Follow-up data for the cohort of patients was updated to November 1, 2004.
All death certificates were reviewed. If autopsy had been performed, the autopsy report was studied to validate the cause of death. If uveal melanoma metastases were found at autopsy, the patient was coded as having died of melanoma. If no autopsy had been performed and uveal melanoma was registered on the death certificate as the cause of death and the patient had no other malignancies according to the DCR, the patient was coded as having died of melanoma. If uveal melanoma or other malignancies were not noted on the death certificate and the patient was registered exclusively in the DCR with uveal melanoma, the patient was coded as having died of a nonmelanoma cause. If a malignancy other than uveal melanoma was registered as the cause of death on the death certificate and the patient was registered with this malignancy in the DCR, the patient was coded as having died of a nonmelanoma cause. Finally, if a malignancy other than uveal melanoma was registered as the cause of death but this malignancy was not registered in the DCR, the patient was coded as having died of melanoma (12 cases coded on the death certificate as skin melanoma, eight cases as gastrointestinal cancer, and one as unspecified malignancy). In eight cases, the cause of death could not be determined.
Relationships between optic nerve invasion and clinical parameters were examined by contingency tables and were further analyzed by Pearson χ 2 test and Fisher exact test. Mean age and tumor size were analyzed by t test after verification of equal variances by Levene test. The equality of mean of intraocular pressure was tested by the Mann-Whitney U test because a nonnormal distribution was found. Correlations between ordinal parameters and optic nerve invasion were evaluated by Spearman rank correlation test.
Univariate and multivariate binary logistic regression analyses were performed in a forward stepwise manner to evaluate the predictive value of clinical factors for different degrees of optic nerve invasion. Factors with P < 0.20 in the univariate analysis were included in the multivariate analysis.
Survival data were obtained by the Kaplan-Meier method, and the Mantel-Cox log-rank test was used to test differences in survival between patient groups. Patients were excluded if no follow-up data were obtainable (n = 6). Patients with undetermined causes of death (n = 8) were excluded from the analysis of melanoma-related death. One patient with uveal melanoma diagnosed at autopsy was excluded from the survival analyses. Patients who died of causes unrelated to uveal melanoma were censored at the time of death in the analyses of melanoma-related death. P < 0.05 was regarded as significant.
For a period spanning 60 years (1942–2001), 2758 eyes with uveal melanoma were examined at the Eye Pathology Institute, University of Copenhagen, and the Institute of Pathology, Aarhus University Hospital. Optic nerve invasion was present in 157 cases (5.7%; 95% confidence interval [CI], 4.8%–6.6%). The frequency of optic nerve invasion in uveal melanoma varied between 5% and 7% of all diagnosed uveal melanomas during the observation period
(Fig. 2) . Eighty-five (54%) were confined to the prelaminar or laminar part of the optic nerve, and 72 (46%) were postlaminar
(Fig. 3) . Patient and tumor characteristics are listed in
Table 1 .
The mean age of patients with postlaminar optic nerve invasion was 70 years (95% CI, 67–73 years) compared with 63 years in patients with prelaminar or laminar invasion (95% CI, 60–65 years; P < 0.001) and 61 years in controls (95% CI, 58–64 years; P < 0.001).
Visual acuity was significantly reduced in patients with postlaminar invasion compared with the other patient groups (versus prelaminar or laminar,
P < 0.001; versus control,
P < 0.001;
Table 1 ). Furthermore, patients with prelaminar or laminar invasion had significantly reduced visual acuity compared with controls (
P = 0.027;
Table 1 ).
Patients with postlaminar optic nerve invasion had significantly higher IOP (median, 48 mm Hg; 14–70 mm Hg 10th–90th percentiles) compared with other groups (prelaminar or laminar: median, 17 mm Hg; Hg 10th–90th percentiles, 12–50 mm;
P < 0.001; control: median, 15 mm Hg; 10
th–90th percentiles, 10–38 mm Hg;
P < 0.001;
Table 1 ). In addition, the frequency of increased IOP was higher in patients with prelaminar or laminar optic nerve invasion than in the controls (
P = 0.003;
Table 1 ).
In 38% (95% CI, 24%–52%) of patients with postlaminar invasion, no view of the fundus was obtainable by direct funduscopic examination, primarily because of vitreous hemorrhage or total retinal detachment, compared with only 8% (95% CI, 2%–14%; P < 0.001) among controls.
At direct funduscopic examination, the tumor was observed as juxtapapillary in 66% (95% CI, 48%–83%) of the cases with postlaminar invasion and in 71% (95% CI, 60%–83%) of the cases with prelaminar or laminar invasion
(Table 1) . In 15% (95% CI, 7%–24%) of the controls, the tumor was observed as juxtapapillary.
A significantly higher proportion of tumors with postlaminar invasion (19%) were thought by the surgeon to include extraocular extension compared with those with prelaminar or laminar invasion (5%; P = 0.004). Orbital recurrence was significantly more common among patients with postlaminar invasion (8%; 95% CI, 2%–15%) than in controls (1%; 95% CI, 0%–3%; P < 0.05).
Tumors with postlaminar optic nerve invasion (mean LBD, 16 mm; 95% CI, 14–17 mm) were significantly larger than the other tumors (prelaminar or laminar: mean LBD, 13 mm; 95% CI, 11–14 mm; P = 0.001; controls: mean LBD, 13 mm; 95% CI, 12–14 mm; P < 0.001).
Before enucleation, three patients with prelaminar or laminar optic nerve invasion were treated with Ru-106 brachytherapy; one of those patients was treated twice. Two patients had been treated with transpupillary thermotherapy (TTT) and one (in 1962) with photocoagulation and external radiation. Radiation was used in an attempt to save the eye because the other one was no longer functional. Before enucleation, three patients with postlaminar optic nerve invasion were treated with Ru-106 brachytherapy and two were treated with TTT. In the control group, three patients were treated with Ru-106 brachytherapy and none were treated with TTT.
In addition, before enucleation, six (8%) patients with postlaminar optic nerve invasion, nine (11%) patients with prelaminar or laminar invasion, and eight (9%) patients in the control group had undergone various types of ocular surgery (e.g., iridectomy, sclerotomy).
Univariate binary logistic regression analysis showed that intraocular pressure greater than 24 mm Hg and juxtapapillary location were associated with prelaminar or laminar optic nerve invasion
(Table 2) . The only clinical factor that was significantly associated with prelaminar or laminar optic nerve invasion of uveal melanoma on a multivariate level was juxtapapillary location
(Table 2) .
Age older than 70 years, visual acuity reduced to light perception (LP) or no light perception (NLP), intraocular pressure greater than 24 mm Hg, juxtapapillary location, nonvisible fundus, and largest basal diameter greater than 15 mm were significantly associated with postlaminar optic nerve invasion by univariate binary logistic regression
(Table 2) . Intraocular pressure greater than 24 mm Hg was the only factor associated with postlaminar optic nerve invasion by multivariate regression analysis
(Table 2) .
Metastatic disease was found in 53% of deceased patients with prelaminar or laminar optic nerve invasion and in 63% of patients with postlaminar optic nerve invasion. Metastatic disease developed in 43 (61%) patients in the control group
(Table 3) . The liver was the most frequent site of metastasis in all three patient groups, followed by the lungs
(Table 3) . Evidence of metastasis to the central nervous system (CNS), kidney, heart, or adrenal glands was only found in patients with optic nerve invasion. All five patients with postlaminar optic nerve invasion and metastases to the CNS had invasion of tumor cells into the subarachnoidal space. In two of these patients, the tumor was confined to the subarachnoidal space and the optic nerve sheaths. Significantly more autopsies were performed in patients with prelaminar or laminar invasion than in controls (
P = 0.004;
Table 3 ).
Two hundred thirty-five patients (126 men, 109 women) were included in the survival analysis (all-cause mortality). Median follow-up time for all patients (n = 235) was 50 months (range, 1–660 months), and for patients still alive (n = 35) it was 137 months (range, 28 to 660 months). Median follow-up time was 53 months (range, 3–660 months) for patients with prelaminar or laminar invasion, 23 months (range, 1–495 months) for patients with postlaminar invasion, and 65 months (range, 1–478 months) for patients in the control group.
One-hundred eighteen patients died of uveal melanoma, 74 patients died of other causes, and 35 were still alive at the end of follow-up. In eight patients the cause of death was undetermined. These eight patients were excluded from the analysis of melanoma-related death.
Two hundred twenty-seven patients (120 men, 107 women) were included in the analysis of melanoma-related death. Median follow-up time for all patients (n = 227) was 49 months (range, 1–660 months), and for patients still alive (n = 35) it was 137 months (range, 28–660 months). Median follow-up time was 53 months (range, 3–660 months) for patients with prelaminar or laminar invasion, 23 months (range, 1–495 months) for patients with postlaminar invasion, and 62 months (range, 1–395 months) for patients in the control group.
Significant differences in mortality (all-cause and melanoma-related) were found between patients with postlaminar invasion and controls (all-cause,
P = 0.001; melanoma-related,
P = 0.017) and patients with prelaminar or laminar invasion (all-cause,
P = 0.001; melanoma-related,
P = 0.004;
Figs. 4A 4B ). No significant differences in mortality were found between patients with prelaminar or laminar invasion and controls (all-cause,
P = 0.93; melanoma-related,
P = 0.49;
Figs. 4A 4B ).
This study identified juxtapapillary tumor location, reduced visual acuity, and increased intraocular pressure as predictive of invasion of the optic nerve in patients with uveal melanoma. Invasion of the optic nerve was found in 5% of all enucleated eyes with uveal melanoma, and it was associated with poor prognosis because of the large tumor size and the high frequency of orbital recurrences.
Supported by grants from Synoptikfonden, Købmand M. Kristian Kjær og hustru Margrethe Kjær født la Cour-Holmen’s Fond, Overlærer Svend Hansen’s Fond, Værn om Synet, Savværksejer Jeppe Juhl og Hustru Ovita Juhls Mindelegat, H:S Generelle Forskningspulje, and The Danish Cancer Society.
Submitted for publication November 7, 2005; revised February 2 and March 22, 2006; accepted June 19, 2006.
Disclosure:
J. Lindegaard, None;
P. Isager, None;
J.U. Prause, None;
S. Heegaard, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked “
advertisement” in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Corresponding author: Jens Lindegaard, Eye Pathology Institute, Frederik V’s Vej 11, 1 floor, DK-2100 Copenhagen, Denmark;
[email protected].
Table 1. Clinical Characteristics in 242 Patients with Uveal Melanoma with and without Optic Nerve Invasion
Table 1. Clinical Characteristics in 242 Patients with Uveal Melanoma with and without Optic Nerve Invasion
Characteristic | Optic Nerve Invasion | | | P |
| Prelaminar/Laminar n (%) | Postlaminar n (%) | No (control) n (%) | |
Sex | n = 85 | n = 72 | n = 85 | 0.79* , §; 0.36, † , §; 0.22, ‡ , § |
Male | 49 (48) | 40 (57) | 41 (48) | |
Female | 36 (52) | 32 (43) | 44 (52) | |
Age, y | n = 85 | n = 72 | n = 85 | <0.001* , ∥; <0.001, † , ∥; 0.46, ‡ , ∥ |
Mean (95% CI) | 63 (60–65) | 70 (67–73) | 61 (58–64) | |
Range | 31–91 | 42–92 | 23–87 | |
Visual acuity | n = 59 | n = 55 | n = 76 | <0.001* , ¶; <0.001, † , ¶; 0.027, ‡ , ¶ |
6/6-6/12 | 12 (20) | 1 (2) | 18 (24) | |
6/18-6/60 | 10 (17) | 2 (4) | 25 (33) | |
5/60-HM | 17 (29) | 5 (9) | 20 (26) | |
LP, # | 6 (10) | 12 (22) | 6 (8) | |
NLP, ** | 14 (24) | 35 (63) | 7 (9) | |
Intraocular pressure (mm Hg) | n = 38 | n = 34 | n = 68 | <0.001* , ¶; <0.001, † , ¶; 0.003, ‡ , ¶ |
≤24 mm Hg | 25 (66) | 7 (20) | 61 (90) | |
>24–40 mm Hg | 4 (11) | 4 (12) | 1 (1) | |
>40 mm Hg | 9 (23) | 23 (68) | 6 (9) | |
Mean | 25 | 44 | 20 | <0.001* , ††; <0.001†††; 0.065, ‡ , †† |
10th–90th percentile | 12–50 | 14–70 | 10–38 | |
Range | 8–62 | 10–79 | 8–90 | |
Fundus examination | n = 62 | n = 47 | n = 78 | <0.001* , §; <0.001, † , §; 0.68, ‡ , § |
Observable fundus | 56 (90) | 29 (62) | 72 (92) | |
No view | 6 (10) | 18 (38) | 6 (8) | |
Juxtapapillary location | n = 56 | n = 29 | n = 72 | 0.58* , §; <0.001, † , §; <0.001, ‡ , § |
Yes | 40 (71) | 19 (66) | 11 (15) | |
No | 16 (29) | 10 (34) | 61 (85) | |
Extraocular extension suspected at surgery | n = 85 | n = 72 | n = 85 | 0.004* , §; 0.12, † , §; 0.15, ‡ , § |
Yes | 4 (5) | 14 (19) | 9 (11) | |
No | 81 (95) | 58 (81) | 76 (89) | |
Orbital recurrence | n = 85 | n = 72 | n = 85 | 0.090* , §; 0.030, † , §; 0.56, ‡ , § |
Yes | 2 (2) | 6 (8) | 1 (1) | |
No | 83 (98) | 66 (92) | 84 (99) | |
Tumor size (mm) | n = 85 | n = 72 | n = 85 | <0.001* , ¶; <0.001, † , ¶; 0.88, ‡ , ¶ |
Small (≤10 mm) | 37 (44) | 14 (19) | 32 (38) | |
Medium (>10–15 mm) | 29 (34) | 25 (35) | 39 (46) | |
Large (>15 mm) | 19 (22) | 33 (46) | 14 (16) | |
Mean (95% CI) | 13 (11–14) | 16 (14–17) | 13 (12–14) | |
Range | 3–35 | 4–40 | 4–30 | <0.001* , ∥; <0.001, † , ∥; 0.92, ‡ , ∥ |
Table 2. Association of Clinical Factors with Prelaminar/Laminar and Postlaminar Optic Nerve Invasion of Uveal Melanoma, Evaluated by Univariate and Multivariate Binary Logistic Regression
Table 2. Association of Clinical Factors with Prelaminar/Laminar and Postlaminar Optic Nerve Invasion of Uveal Melanoma, Evaluated by Univariate and Multivariate Binary Logistic Regression
Selected Variable | Prelaminar/Laminar Optic Nerve Invasion | | | | Postlaminar Optic Nerve Invasion | | | |
| Univariate Logistic Regression | | Multivariate Logistic Regression* , † (n = 95) | | Univariate Logistic Regression | | Multivariate Logistic Regression, † , ‡ (n = 86) | |
| OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
Sex | | | | | | | | |
Female (reference) | | | | | | | | |
Male | 1.46 (0.80–2.68) | 0.22 | | | 1.34 (0.72–2.52) | 0.36 | | |
Age, y | | 0.97 | | | | <0.001 | | |
<50 (reference) | | | | | | | | |
≥50–60 | 1.01 (0.39–2.63) | 0.98 | | | 1.52 (0.42–5.45) | 0.52 | | |
≥60–70 | 1.03 (0.44–2.45) | 0.94 | | | 1.76 (0.55–5.63) | 0.34 | | |
≥70–80 | 1.14 (0.42–3.08) | 0.80 | | | 5.55 (1.69–18.2) | 0.005 | | |
≥80 | 1.60 (0.38–6.81) | 0.53 | | | 12.0 (2.70–53.3) | 0.001 | | |
Visual acuity | | 0.10 | | | | <0.001 | | |
6/6-6/12 (reference) | | | | | | | | |
6/18-6/60 | 0.60 (0.21–1.69) | 0.33 | | | 1.44 (0.12–17.1) | 0.77 | | |
5/60-HM | 1.28 (0.48–3.38) | 0.63 | | | 4.50 (0.48–42.2) | 0.19 | | |
LP | 1.50 (0.39–5.77) | 0.56 | | | 36.0 (3.84–338) | 0.002 | | |
NLP | 3.00 (0.94–9.62) | 0.07 | | | 90.0 (10.3–789) | <0.001 | | |
Intraocular pressure, mm Hg | | 0.016 | | | | <0.001 | | <0.001 |
≤24 (reference) | | | | | | | | |
>24–40 | 9.76 (1.04–91.7) | 0.046 | | | 34.9 (3.40–357) | 0.003 | 76.0 (6.37–907), § | 0.001 |
>40 | 3.66 (1.18–11.4) | 0.025 | | | 33.4 (10.2–110) | <0.001 | 47.5 (10.6–212), § | <0.001 |
Fundoscopic examination | | | | | | | | |
Observable fundus (reference) | | | | | | | | |
No view | 1.29 (0.39–4.20) | 0.68 | | | 7.45 (2.69–20.6) | <0.001 | | |
Juxtapapillary location | | | | | | | | |
No (reference) | | | | | | | | |
Yes | 13.9 (5.84–32.9) | <0.001 | 14.0 (4.67–41.9), § | <0.001 | 10.5 (3.88–28.6) | <0.001 | | |
Extraocular extension | | | | | | | | |
No (reference) | | | | | | | | |
Yes | 0.42 (0.12–1.41) | 0.16 | | | 2.04 (0.83–5.04) | 0.12 | | |
Tumor size, mm | | 0.28 | | | | <0.001 | | |
≤10 (reference) | | | | | | | | |
>10–15 | 0.64 (0.33–1.26) | 0.20 | | | 1.47 (0.66–3.27) | 0.35 | | |
>15 | 1.17 (0.51–2.71) | 0.71 | | | 5.39 (2.22–13.1) | <0.001 | | |
Table 3. Autopsy Rates and Metastatic Patterns in Patients with Uveal Melanoma with and without Optic Nerve Invasion
Table 3. Autopsy Rates and Metastatic Patterns in Patients with Uveal Melanoma with and without Optic Nerve Invasion
| Optic Nerve Invasion | | | P |
| Prelaminar/Laminar n (% [95% CI]) | Postlaminar n (% [95% CI]) | No (control) n (% [95% CI]) | |
Deaths | 62 | 68 | 71 | |
Autopsies | 22 (35) | 16 (24) | 10 (14) | 0.13* , § |
| | | | 0.15, † , § |
| | | | 0.004, ‡ , § |
Metastases | 33 (53) | 43 (63) | 43 (61) | 0.25* , § |
| | | | 0.75, † , § |
| | | | 0.40, ‡ , § |
Metastatic location known, ∥ | 26 | 36 | 34 | |
Liver | 22 (85 [71–99]) | 27 (75 [60–89]) | 31 (91 [82–100]) | |
Lung | 7 (27 [10–44]) | 11 (31 [16–46]) | 6 (18 [5–30]) | |
Bone | 5 (19 [4–34]) | 5 (14 [3–25]) | 3 (9 [0–18]) | |
Skin | 4 (15 [2–29]) | 4 (11 [1–21]) | 2 (6 [0–14]) | |
CNS | 1 (4 [0–11]) | 5 (14 [3–25]), ¶ | 0 (0) | |
Kidney | 3 (12 [0–24]) | 3 (8 [0–17]) | 0 (0) | |
Heart | 4 (15 [2–29]) | 1 (3 [0–8]) | 0 (0) | |
Lymph node | 4 (15 [2–29]) | 1 (3 [0–8]) | 1 (3 [0–9]) | |
Adrenal gland | 5 (19 [4–34]) | 0 (0) | 0 (0) | |
Other | 10 (38 [20–57]) | 3 (8 [0–17]) | 4 (12 [1–23]) | |
The authors thank Torben Steiniche for providing access to the material on uveal melanoma at the Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark.
BergmanL, SeregardS, NilssonB, RingborgU, LundellG, Ragnarsson-OldingB. Incidence of uveal melanoma in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci. 2002;43:2579–2583.
[PubMed]RaivioI. Uveal melanoma in Finland: an epidemiological, clinical, histological and prognostic study. Acta Ophthalmol Suppl. 1977.1–64.
JensenOA. Malignant melanomas of the uvea in Denmark 1943–1952: a clinical, histopathological, and prognostic study. Acta Ophthalmol (Copenh). 1963;43(suppl)220.
IsagerP, OsterlindA, EngholmG, et al. Uveal and conjunctival malignant melanoma in Denmark, 1943–97: incidence and validation study. Ophthalmic Epidemiol. 2005;12:223–232.
[CrossRef] [PubMed]LoriganJG, WallaceS, MavligitGM. The prevalence and location of metastases from ocular melanoma: imaging study in 110 patients. AJR Am J Roentgenol. 1991;157:1279–1281.
[CrossRef] [PubMed]Collaborative Ocular Melanoma Study. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001;119:670–676.
[CrossRef] [PubMed]ShammasHF, BlodiFC. Peripapillary choroidal melanomas: extension along the optic nerve and its sheaths. Arch Ophthalmol. 1978;96:440–445.
[CrossRef] [PubMed]LindegaardJ, HeegaardS, PrauseJU. Histopathologically verified non-vascular optic nerve lesions in Denmark 1940–99. Acta Ophthalmol Scand. 2002;80:32–37.
[PubMed]ChristmasNJ, MeadMD, RichardsonEP, AlbertDM. Secondary optic nerve tumors. Surv Ophthalmol. 1991;36:196–206.
[CrossRef] [PubMed]McLeanMJ, FosterWD, ZimmermanLE. Prognostic factors in small malignant melanomas of choroid and ciliary body. Arch Ophthalmol. 1977;95:48–58.
[CrossRef] [PubMed]WilderHC, PaulEV. Malignant melanoma of the choroid and ciliary body: a study of 2,535 cases. Milit Surg. 1951;109:370–378.
ReeseAB. Pigmented tumors.ReeseAB eds. Tumors of the Eye. 1976; 3rd ed. 173–262.Harper & Row Hagerstown, MD.
WeinhausRS, SeddonJM, AlbertDM, GragoudasES, RobinsonN. Prognostic factor study of survival after enucleation for juxtapapillary melanomas. Arch Ophthalmol. 1985;103:1673–1677.
[CrossRef] [PubMed]Collaborative Ocular Melanoma Study. Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study: COMS report no. 6. Am J Ophthalmol. 1998;125:745–766.
[CrossRef] [PubMed]SpencerWH. Optic nerve extension of intraocular neoplasms. Am J Ophthalmol. 1975;80:465–471.
[CrossRef] [PubMed]ShieldsCL, ShieldsJA, YarianDL, AugsburgerJJ. Intracranial extension of choroidal melanoma via the optic nerve. Br J Ophthalmol. 1987;71:172–176.
[CrossRef] [PubMed]al HaddabS, HidayatA, TabbaraKF. Ciliary body melanoma with optic nerve invasion. Br J Ophthalmol. 1990;74:123–124.
[CrossRef] [PubMed]ChessJ, AlbertDM, BellowsAR, DallowR. Uveal melanoma: case report of extension through the optic nerve to the surgical margin in the orbital apex. Br J Ophthalmol. 1984;68:272–275.
[CrossRef] [PubMed]McLeanIW, FosterWD, ZimmermanLE, MartinDG. Inferred natural history of uveal melanoma. Invest Ophthalmol Vis Sci. 1980;19:760–770.
[PubMed]ShieldsCL, ShieldsJA, ShieldsMB, AugsburgerJJ. Prevalence and mechanisms of secondary intraocular pressure elevation in eyes with intraocular tumors. Ophthalmology. 1987;94:839–846.
[CrossRef] [PubMed]GiarelliL, FalconieriG, CameronJD, PheleyAM. Schnabel cavernous degeneration: a vascular change of the aging eye. Arch Pathol Lab Med. 2003;127:1314–1319.
[PubMed]Abdel-RahmanMH, CraigEL, DavidorfFH, EngC. Expression of vascular endothelial growth factor in uveal melanoma is independent of 6p21-region copy number. Clin Cancer Res. 2005;11:73–78.
[PubMed]WalkerTM, Van GinkelPR, GeeRL, et al. Expression of angiogenic factors Cyr61 and tissue factor in uveal melanoma. Arch Ophthalmol. 2002;120:1719–1725.
[CrossRef] [PubMed]BoydSR, TanDS, de SouzaL, et al. Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. Br J Ophthalmol. 2002;86:440–447.
[CrossRef] [PubMed]SaitohA, TaniguchiH, GongH, OhiraA, AmemiyaT, BabaT. Long-term effect on optic nerve of silicone oil tamponade in rabbits: histological and EDXA findings. Eye. 2002;16:171–176.
[CrossRef] [PubMed]AffeldtJC, MincklerDS, AzenSP, YehL. Prognosis in uveal melanoma with extrascleral extension. Arch Ophthalmol. 1980;98:1975–1979.
[CrossRef] [PubMed]DonosoLA, BerdD, AugsburgerJJ, MastrangeloMJ, ShieldsJA. Metastatic uveal melanoma: pretherapy serum liver enzyme and liver scan abnormalities. Arch Ophthalmol. 1985;103:796–798.
[CrossRef] [PubMed]AlbertDM, RyanLM, BordenEC. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol. 1996;114:107–108.
[CrossRef] [PubMed]LeiterU, MeierF, SchittekB, GarbeC. The natural course of cutaneous melanoma. J Surg Oncol. 2004;86:172–178.
[CrossRef] [PubMed]LommatzschP, DietrichB. Survival rate of patients with choroidal melanoma. Ophthalmologica. 1976;173:453–462.
[CrossRef] [PubMed]MakitieT, KivelaT. Cardiac metastasis from uveal melanoma. Arch Ophthalmol. 2001;119:139–140.
[PubMed]RuizRS, El HaraziS, AlbertDM, BryarPJ. Cardiac metastasis of choroidal melanoma. Arch Ophthalmol. 1999;117:1558–1559.
[PubMed]BedikianAY, KantarjianH, YoungSE, BodeyGP. Prognosis in metastatic choroidal melanoma. South Med J. 1981;74:574–577.
[CrossRef] [PubMed]MadajewiczS, KarakousisC, WestCR, CaracandasJ, AvellanosaAM. Malignant melanoma brain metastases: review of Roswell Park Memorial Institute experience. Cancer. 1984;53:2550–2552.
[CrossRef] [PubMed]Cohn-CedermarkG, Mansson-BrahmeE, RutqvistLE, LarssonO, JohanssonH, RingborgU. Central nervous system metastases of cutaneous malignant melanoma—a population-based study. Acta Oncol. 1998;37:463–470.
[CrossRef] [PubMed]HerlynM, ThurinJ, BalabanG, et al. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res. 1985;45:5670–5676.
[PubMed]ReeAH, BratlandA, KroesRA, et al. Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases. Anticancer Res. 2002;22:1949–1957.
[PubMed]D’AmicoTA, AloiaTA, MooreMB, et al. Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg. 2001;72:1144–1148.
[CrossRef] [PubMed]IsagerP, EhlersN, OvergaardJ. Prognostic factors for survival after enucleation for choroidal and ciliary body melanomas. Acta Ophthalmol Scand. 2004;82:517–525.
[CrossRef] [PubMed]Diener-WestM, EarleJD, FineSL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. Arch Ophthalmol. 2001;119:969–982.
[CrossRef] [PubMed]KujalaE, MakitieT, KivelaT. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:4651–4659.
[CrossRef] [PubMed]SeregardS, KockE. Prognostic indicators following enucleation for posterior uveal melanoma: a multivariate analysis of long-term survival with minimized loss to follow-up. Acta Ophthalmol Scand. 1995;73:340–344.
[PubMed]SeregardS, SpangbergB, JuulC, OskarssonM. Prognostic accuracy of the mean of the largest nucleoli, vascular patterns, and PC-10 in posterior uveal melanoma. Ophthalmology. 1998;105:485–491.
[CrossRef] [PubMed]